Clinicopathologic characteristics, genetic variability and therapeutic options of RET rearrangements patients in lung adenocarcinoma
- 1 November 2016
- journal article
- Published by Elsevier BV in Lung Cancer
- Vol. 101, 16-21
- https://doi.org/10.1016/j.lungcan.2016.09.002
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non–Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II TrialJournal of Clinical Oncology, 2015
- The RET fusion gene and its correlation with demographic and clinicopathological features of non-small cell lung cancer: a meta-analysisCancer Biology & Therapy, 2015
- ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: A comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic featuresLung Cancer, 2014
- Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohortsBritish Journal of Cancer, 2014
- Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking doseLung Cancer, 2013
- Frequency of Driver Mutations in Lung Adenocarcinoma from Female Never-Smokers Varies with Histologic Subtypes and Age at DiagnosisClinical Cancer Research, 2012
- Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsiesNature Medicine, 2012
- A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencingGenome Research, 2011
- Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant KinasesJournal of Clinical Oncology, 2010
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2008